Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

Basit Öğe Kaydı
dc.contributor.authorGevaert, Thomas
dc.contributor.authorMontironi, Rodolfo
dc.contributor.authorLopez-Beltran, Antonio
dc.contributor.authorVan Leenders, Geert
dc.contributor.authorAllory, Yves
dc.contributor.authorDe Ridder, Dirk
dc.contributor.authorClaessens, Frank
dc.date.accessioned2020-03-26T19:54:04Z
dc.date.available2020-03-26T19:54:04Z
dc.date.issued2018
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractImmunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.en_US
dc.identifier.doi10.1016/j.semcancer.2017.10.004en_US
dc.identifier.endpage227en_US
dc.identifier.issn1044-579Xen_US
dc.identifier.issn1096-3650en_US
dc.identifier.pmid29032188en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage216en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.semcancer.2017.10.004
dc.identifier.urihttps://hdl.handle.net/20.500.12395/36656
dc.identifier.volume52en_US
dc.identifier.wosWOS:000446285900023en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDen_US
dc.relation.ispartofSEMINARS IN CANCER BIOLOGYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectImmunotherapyen_US
dc.subjectBladderen_US
dc.subjectKidneyen_US
dc.subjectProstateen_US
dc.subjectBiomarkersen_US
dc.titleGenito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatmenten_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu